<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293436</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000458055</org_study_id>
    <secondary_id>UCSF-04459</secondary_id>
    <secondary_id>UCSF-H43059-26066-02</secondary_id>
    <nct_id>NCT00293436</nct_id>
  </id_info>
  <brief_title>Celecoxib and Erlotinib in Treating Patients With Liver Cancer</brief_title>
  <official_title>A Phase I/II Study of Celecoxib and Erlotinib Hydrochloride as Adjuvant Therapy for High Risk Patients With a History of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib and erlotinib may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for their growth. Celecoxib may also stop the growth of liver cancer by&#xD;
      blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of giving celecoxib&#xD;
      together with erlotinib and to see how well they work in treating patients with liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of adjuvant celecoxib and erlotinib hydrochloride for patients with&#xD;
           hepatocellular carcinoma (HCC) at high risk for recurrence. (phase I)&#xD;
&#xD;
        -  Assess disease-free and overall survival of patients treated with adjuvant celecoxib and&#xD;
           erlotinib hydrochloride. (phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of celecoxib and erlotinib hydrochloride for the&#xD;
           phase II portion of this trial. (phase I)&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study followed by an open-label, phase II study.&#xD;
      Patients are assigned to a treatment according to Child-Pugh class of cirrhosis (class&#xD;
      A/noncirrhotic vs class B).&#xD;
&#xD;
        -  Phase I: Patients receive oral celecoxib once or twice daily and oral erlotinib&#xD;
           hydrochloride once daily. Treatment continues for up to 6 months in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of celecoxib and erlotinib hydrochloride&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 6 patients experience dose-limiting toxicity. Separate dose&#xD;
      escalations are conducted in the 2 groups according to liver dysfunction.&#xD;
&#xD;
        -  Phase II: Patients receive celecoxib and erlotinib hydrochloride as in phase I at the&#xD;
           MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2005</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival (phase II)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose (phase I)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (phase II)</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histological evidence of hepatocellular carcinoma (HCC)&#xD;
&#xD;
               -  No evidence of residual or recurrent disease&#xD;
&#xD;
          -  Received 1 of the following therapies:&#xD;
&#xD;
               -  Tumor resection between 4-8 weeks prior to study enrollment&#xD;
&#xD;
               -  Transarterial chemo-embolization between the past 4-8 weeks&#xD;
&#xD;
               -  Radiofrequency ablation and percutaneous ethanol injection (sequential or&#xD;
                  combinations thereof) between the past 2-8 weeks&#xD;
&#xD;
          -  Meets 1 of the following high-risk features for recurrence:&#xD;
&#xD;
               -  History of resection of a single HCC &gt; 5 cm&#xD;
&#xD;
               -  History of multifocal HCC (includes microsatellite disease found at time of&#xD;
                  resection)&#xD;
&#xD;
               -  History of vascular invasion (macro or micro)&#xD;
&#xD;
               -  History of poorly differentiated HCC&#xD;
&#xD;
               -  Underlying cirrhosis&#xD;
&#xD;
          -  No Child-Pugh class C cirrhosis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST/ALT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times ULN&#xD;
&#xD;
          -  INR ≤ 1.5 times ULN&#xD;
&#xD;
          -  Albumin ≥ 2.5 g/dL&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 2 years&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  Patients must agree not to wear contact lenses&#xD;
&#xD;
          -  No history of ulcer disease or gastrointestinal bleeding&#xD;
&#xD;
          -  No myocardial infarction within the past 18 months&#xD;
&#xD;
          -  No cerebral vascular event within the past 18 months&#xD;
&#xD;
          -  No history of aspirin or NSAID-induced asthma&#xD;
&#xD;
          -  No history of Gilbert's syndrome&#xD;
&#xD;
          -  No history of hypersensitivity reaction or allergy to sulfa drugs, aspirin, or other&#xD;
             NSAIDs&#xD;
&#xD;
          -  No liver transplantation candidates for phase I portion of the study&#xD;
&#xD;
          -  No New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
          -  No interstitial lung disease&#xD;
&#xD;
          -  No gastrointestinal disease prohibiting oral medication or requiring IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No ongoing, active, or untreated infection&#xD;
&#xD;
          -  No hypersensitivity to celecoxib&#xD;
&#xD;
          -  No rising alpha-fetal protein (AFP) not attributable to hepatitis B or C virus&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior liver transplantation&#xD;
&#xD;
          -  No prior chemotherapy or biologic therapy in the adjuvant setting&#xD;
&#xD;
          -  No prior chest or mantle radiotherapy&#xD;
&#xD;
          -  No concurrent aspirin or other nonsteroidal anti-inflammatory drug (NSAID)&#xD;
&#xD;
          -  No concurrent interferon&#xD;
&#xD;
          -  No concurrent oral steroids&#xD;
&#xD;
          -  No concurrent anticoagulant therapy&#xD;
&#xD;
          -  No concurrent CYP3A4 inducers or inhibitors&#xD;
&#xD;
          -  No concurrent commercial or other investigational anticancer agents or therapies&#xD;
&#xD;
          -  No concurrent selective cyclooxygenase-2 inhibitors&#xD;
&#xD;
          -  No concurrent antineoplastic or antitumor agents, including chemotherapy,&#xD;
             radiotherapy, immunotherapy, or hormonal anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan P. Venook, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2012</last_update_posted>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized resectable adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

